Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | HTR1B | P28222 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24776438 | 0.85 | ALDH1A1 (0.39) | ALDH1A1TSHRHSD17B10CYP2A6CYP3A4 | |
| SCHEMBL7853160 | 0.84 | TAAR1 (0.48) | ALDH1A1TSHRHSD17B10CYP2A6CYP3A4 | |
| Hydrochloric Acid SCHEMBL7600295 | 0.83 | ALDH1A1 (0.38) | ALDH1A1TSHRHSD17B10CYP2A6CYP3A4 | |
| SCHEMBL7192329 | 0.81 | ALDH1A1 (0.38) | ALDH1A1TSHRHSD17B10CYP2A6CYP3A4 | |
| SCHEMBL4667119 | 0.80 | KIF11 (0.37) | ALDH1A1TSHRHSD17B10CYP2A6CYP3A4 | |
| SCHEMBL1465980 | 0.80 | ALDH1A1 (0.41) | ALDH1A1TSHRHSD17B10CYP2A6CYP3A4 | |
| SCHEMBL1321899 | 0.79 | ALDH1A1 (0.44) | ALDH1A1TSHRHSD17B10CYP2A6CYP3A4 | |
| SCHEMBL30344974 | 0.79 | ALDH1A1 (0.44) | ALDH1A1TSHRHSD17B10CYP2A6CYP3A4 | |
| SCHEMBL3681420 | 0.79 | ALDH1A1 (0.44) | ALDH1A1TSHRHSD17B10CYP2A6CYP3A4 | |
| SCHEMBL23732409 | 0.79 | ALDH1A1 (0.38) | ALDH1A1TSHRHSD17B10CYP2A6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268894-B2 | Compositions and methods for the treatment of infectious diseases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-18 | — | — | US | disclosed |
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-05-19 | — | — | US | disclosed |
| US-7842729-B2 | Anti tubercular drug: compositions and methods | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7456222-B2 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-01-26 | — | — | US | disclosed |
| US-6951961-B2 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2005-10-04 | — | — | US | disclosed |
| US-6699873-B1 | EATING DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | TERT, C5, ELANE | ALDH1A1 1876/4885TSHR 2407/4885HSD17B10 2967/4885 |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | RIF1, TERT, ELL | ALDH1A1 1029/4885TSHR 2423/4885HSD17B10 3286/4885 |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | ALDH1A1 1277/4885TSHR 3129/4885HSD17B10 3186/4885 |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | ALDH1A1 1277/4885TSHR 3129/4885HSD17B10 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.